Lv7
4620 积分 2024-05-28 加入
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
27天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
1个月前
已完结
Development of improved SRC-3 inhibitors as breast cancer therapeutic agents
1个月前
已关闭
A patent review of BRD4 inhibitors (2013-2019)
1个月前
已完结
BET inhibitors: an updated patent review (2018–2021)
1个月前
已完结
Successes and challenges in the development of BD1-selective BET inhibitors: a patent review
1个月前
已完结
A patent review of BRD4 inhibitors (2020-present)
1个月前
已完结
An updated patent review of BRD4 degraders
1个月前
已完结
Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
3个月前
已完结
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid Malignancies
3个月前
已关闭
皖公网安备34019202002308
